SCHEMBL21217871

SCHEMBL21217871

CC(C)NC(=O)COc1cccc(C(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.56
KMT2A Q03164 2/20 0.56
NR1H4 Q96RI1 3/20 0.53
NR4A2 P43354 1/20 0.52
LMNA P02545 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
PLA2G4B P0C869 1/20 0.52
MEN1 O00255 1/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26119130 0.87 SMN1; SMN2 (0.53) HSD17B10KMT2ALMNAL3MBTL1SMN1; SMN2
SCHEMBL26388731 0.87 L3MBTL1 (0.55) HSD17B10KMT2ALMNAL3MBTL1SMN1; SMN2
SCHEMBL30634522 0.87 SMN1; SMN2 (0.53) HSD17B10KMT2ALMNAL3MBTL1SMN1; SMN2
SCHEMBL26388857 0.86 LMNA (0.63) HSD17B10LMNAL3MBTL1SMN1; SMN2RAB9A
SCHEMBL10765557 0.83 SMN1; SMN2 (0.63) HSD17B10KMT2ALMNAL3MBTL1SMN1; SMN2
SCHEMBL21349076 0.82 SMN1; SMN2 (0.72) HSD17B10KMT2ALMNAL3MBTL1SMN1; SMN2
SCHEMBL6538992 0.82 GAA (0.61) KMT2ALMNAL3MBTL1SMN1; SMN2PLA2G4B
SCHEMBL5487993 0.82 NR4A2 (0.58) KMT2ANR4A2SMN1; SMN2PLA2G4BMEN1
SCHEMBL8251623 0.81 SMN1; SMN2 (0.62) HSD17B10LMNAL3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL21348646 0.81 FFAR1 (0.55) HSD17B10KMT2ALMNAL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223279-A1 PROCESS FOR THE PREPARATION OF BELUMOSUDIL MESYLATE AND ITS CRYSTALLINE FORM ALIVUS LIFE SCIENCES LIMITED (IN) 2025-07-10 US claimed
EP-4499600-A1 PROCESS FOR THE PREPARATION OF BELUMOSUDIL MESYLATE AND ITS CRYSTALLINE FORM Glenmark Life Sciences Limited (IN) 2025-02-05 EP claimed
WO-2023187697-A1 PROCESS FOR THE PREPARATION OF BELUMOSUDIL MESYLATE AND ITS CRYSTALLINE FORM GLENMARK LIFE SCIENCES LIMITED (IN) 2023-10-05 WO claimed
US-20250223279-A1 PROCESS FOR THE PREPARATION OF BELUMOSUDIL MESYLATE AND ITS CRYSTALLINE FORM ALIVUS LIFE SCIENCES LIMITED (IN) 2025-07-10 US disclosed
EP-4499600-A1 PROCESS FOR THE PREPARATION OF BELUMOSUDIL MESYLATE AND ITS CRYSTALLINE FORM Glenmark Life Sciences Limited (IN) 2025-02-05 EP disclosed
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2024-07-04 US disclosed
WO-2023187697-A1 PROCESS FOR THE PREPARATION OF BELUMOSUDIL MESYLATE AND ITS CRYSTALLINE FORM GLENMARK LIFE SCIENCES LIMITED (IN) 2023-10-05 WO disclosed
WO-2023187697-A1 PROCESS FOR THE PREPARATION OF BELUMOSUDIL MESYLATE AND ITS CRYSTALLINE FORM GLENMARK LIFE SCIENCES LIMITED (IN) 2023-10-05 WO disclosed
US-20230021916-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2023-01-26 US disclosed
EP-4026834-A1 HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE Redx Pharma Plc (GB) 2022-07-13 EP disclosed
EP-3743420-B1 HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA PLC (GB) 2021-12-15 EP disclosed
US-20210038606-A1 Modulators of Rho-associated Protein Kinase REDX PHARMA LIMITED (GB) 2021-02-11 US disclosed
WO-2019145729-A9 HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA PLC (GB) 2020-07-30 WO disclosed
WO-2019145729-A1 HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA PLC (GB) 2019-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK2, ROCK1, RHOA HSD17B10 3389/4885KMT2A 2289/4885NR1H4 1402/4885
US-20210038606-A1 Modulators of Rho-associated Protein Kinase ROCK2, ROCK1, RHOA HSD17B10 3224/4885KMT2A 2192/4885NR1H4 1470/4885
US-20250223279-A1 PROCESS FOR THE PREPARATION OF BELUMOSUDIL MESYLATE AND ITS CRYSTALLINE FORM ROCK1, PDE5A, SQLE HSD17B10 1625/4885KMT2A 2614/4885NR1H4 511/4885
US-20230021916-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK2, ROCK1, RHOA HSD17B10 3389/4885KMT2A 2289/4885NR1H4 1402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.